RXII vs. ARDS, BCEL, ARAV, PHIO, SXTP, REVB, NBY, AGRX, RNAZ, and ONCO
Should you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include Aridis Pharmaceuticals (ARDS), Atreca (BCEL), Aravive (ARAV), Phio Pharmaceuticals (PHIO), 60 Degrees Pharmaceuticals (SXTP), Revelation Biosciences (REVB), NovaBay Pharmaceuticals (NBY), Agile Therapeutics (AGRX), TransCode Therapeutics (RNAZ), and Onconetix (ONCO). These companies are all part of the "medical" sector.
RXi Pharmaceuticals (NASDAQ:RXII) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations, community ranking and risk.
Aridis Pharmaceuticals has a net margin of -5.11% compared to RXi Pharmaceuticals' net margin of -4,990.20%. Aridis Pharmaceuticals' return on equity of 0.00% beat RXi Pharmaceuticals' return on equity.
9.6% of RXi Pharmaceuticals shares are held by institutional investors. Comparatively, 9.7% of Aridis Pharmaceuticals shares are held by institutional investors. 1.0% of RXi Pharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
RXi Pharmaceuticals received 70 more outperform votes than Aridis Pharmaceuticals when rated by MarketBeat users. Likewise, 68.09% of users gave RXi Pharmaceuticals an outperform vote while only 61.00% of users gave Aridis Pharmaceuticals an outperform vote.
Aridis Pharmaceuticals has a consensus price target of $2.00, suggesting a potential upside of 2,976.92%. Given Aridis Pharmaceuticals' higher possible upside, analysts plainly believe Aridis Pharmaceuticals is more favorable than RXi Pharmaceuticals.
RXi Pharmaceuticals has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
RXi Pharmaceuticals has higher earnings, but lower revenue than Aridis Pharmaceuticals. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, RXi Pharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.
Summary
Aridis Pharmaceuticals beats RXi Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get RXi Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RXi Pharmaceuticals Competitors List
Related Companies and Tools
